Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial to Investigate the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Next Previous
X
Search
Trial Profile

A Phase II Trial to Investigate the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Rituximab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms PembroWM

    • Most Recent Events

    • 01 Dec 2024 Results (n=17) investigating the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenstroms Macroglobulinaemia, published in the British Journal of Haematology
    • 13 Dec 2022 Status changed from recruiting to discontinued, according to presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 13 Dec 2022 Results assessing safety, tolerability and efficacy of pembrolizumab in combination with rituximab for the treatment of relapsed/refractory Waldenstroms macroglobulinaemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top